Treatment of advanced or recurrent colorectal cancer with irinotecan in Japan and elsewhere

By Sato Takeo   Hatate Kazuhiko   Ikeda Atsushi   Yamanashi Takahiro   Ozawa Heita   Onosato Wataru   Nakamura Takatoshi   Ihara Atsushi   Watanabe Masahiko  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 7, 2008-05 ,pp. : 1223-1228

Informa Healthcare

Access to resources Recommend Favorite

Pharmacogenomics of Fluorouracil, Irinotecan, and Oxaliplatin in Hepatic Metastases of Colorectal Cancer: Clinical Implications

By Lentz Frederike   Tran Agnès   Rey Elisabeth   Pons Gérard   Tréluyer Jean-Marc  

American Journal of PharmacoGenomics, Vol. 5, Iss. 1, 2005-01 ,pp. : 21-33

Adis International

Access to resources Recommend Favorite

Benefit-Risk Assessment of Irinotecan in Advanced Colorectal Cancer

By Glimelius Bengt  

Drug Safety, Vol. 28, Iss. 5, 2005-01 ,pp. : 417-433

Adis International

Access to resources Recommend Favorite

Pharmacokinetic study of oxaliplatin iv chronomodulated infusion combined with 5-fluorouracil iv continuous infusion in the treatment of advanced colorectal cancer

By Cattel L.   La Grotta G.   Infante L.   Passera R.   Arpicco S.   Brusa P.   Bumma C.  

Il Farmaco, Vol. 58, Iss. 12, 2003-12 ,pp. : 1333-1338

Elsevier

Access to resources Recommend Favorite

Combination treatment with gemcitabine, oxaliplatin, fluorouracil and calcium levofolinate in patients with advanced colorectal cancer has high antitumour activity

By  

Inpharma, Vol. 1, Iss. 1445, 2004-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite